Zepbound Outperforms Wegovy in Weight Loss Trial

By Rene Pretorius

December 6, 2024

The news release from Eli Lilly and Company, titled “Lilly’s Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial, highlights the critical comparison of Zepbound vs Wegovy in treating obesity. Zepbound has shown superior efficacy, making it a compelling option for managing weight in adults.

The SURMOUNT-5 trial involved adults living with obesity or overweight with at least one weight-related medical condition but without diabetes. Zepbound outperformed Wegovy on both the primary endpoint and five key secondary endpoints at 72 weeks. The trial demonstrated that Zepbound was superior to Wegovy in terms of weight loss. Participants using Zepbound achieved an average weight loss of 20.2%, compared to 13.7% for those taking Wegovy. In terms of absolute weight loss, those on Zepbound lost 50.3 lbs (22.8 kg), while participants on Wegovy lost 33.1 lbs (15.0 kg). A key secondary endpoint showed that 31.6% of people taking Zepbound achieved at least 25% body weight loss, compared to just 16.1% of those taking Wegovy.

Mechanism of Action – Zepbound vs Wegovy

Tirzepatide, the active ingredient in Zepbound, is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist. In contrast, semaglutide is a mono GLP-1 receptor agonist.

Safety Profile

The overall safety profile of Zepbound in the SURMOUNT-5 trial was similar to previous studies. The most commonly reported adverse events were gastrointestinal-related and generally mild to moderate in severity.

Regulatory and Market Status

Tirzepatide is commercialized as Zepbound for adults with obesity or overweight and weight-related medical problems in some global markets outside the U.S. It received U.S. FDA approval on November 8, 2023, for this indication and is also marketed as Mounjaro for adults with type 2 diabetes.

Ongoing and Future Zepbound Studies

Ongoing studies of tirzepatide focus on its effects in four disease areas. These areas are chronic kidney disease (CKD), morbidity/mortality in obesity (MMO), moderate-to-severe obstructive sleep apnea (OSA), and heart failure with preserved ejection fraction (HFpEF). The data reinforces the efficacy and safety of Zepbound vs Wegovy in managing obesity. Zepbound is a significant treatment option for adults with obesity or those who are overweight and facing related medical challenges.

Reference url

Recent Posts

prior authorization reforms
     

Streamlining Prior Authorization Reforms: Impacts and Insights for HEOR

🚀 Are prior authorizations stalling care delivery in the U.S. healthcare system?

The HHS has launched an ambitious collaboration with major insurers to reform prior authorization processes across Medicare Advantage, Medicaid, and commercial plans. With a goal to standardize submissions by 2027 and significantly reduce requirements by 2026, this initiative promises to accelerate care decisions and enhance transparency.

Dive into the details of these pivotal reforms and discover their potential to streamline healthcare and improve patient outcomes.

#SyenzaNews #HealthcareInnovation #healthcare #healthcarepolicy

private health funding
    

Private Health Funding Under South Africa’s National Health Insurance Act

🚀 Update on NHI in South Africa.

In their insightful article, Solanki et al. discuss the complexities of private health funding amidst the nation’s National Health Insurance Act. They discuss two key scenarios: a passive approach that risks the sustainability of the private sector and an active reform strategy that could ensure a smoother transition to universal coverage.

Curious about how these strategies could reshape healthcare access and costs in South Africa? Don’t miss out on this critical analysis!

#SyenzaNews #HealthEconomics #HealthcarePolicy

drug price transparency
     

Impending Net Drug Price Transparency Regulation in the U.S.

💡 Are you ready for a potential game-changer in drug pricing transparency?

CMS Administrator Mehmet Oz has hinted at a new rule aimed at enforcing stricter disclosures for drug prices, requiring healthcare companies to reveal actual transaction costs. This could reshape how price transparency is managed across the industry and challenge pharmacy benefit managers to rethink rebate practices.

Curious about how this will impact healthcare economics and what it means for drug affordability? Dive into the article for all the insights!

#SyenzaNews #healthcare #HealthEconomics

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.